Acadia Reports Q3 Revenue Beats Expectations and Raises DAYBUE Guidance

Acadia Pharmaceuticals beats Q3 expectations with $342M revenue, raising DAYBUE guidance to $505M-$520M and announcing a new patent extension and FDA Fast Track designation for remlifanserin in Lewy body dementia.